TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) just unveiled an update.
Oncoinvent has announced a Q3 2025 company update, highlighting the promising preliminary clinical efficacy data of their lead product, Radspherin®, which is undergoing trials for treating peritoneal carcinomatoses from ovarian and colorectal cancer. The company reports no serious toxicity or safety concerns, positioning it favorably in the radiopharmaceutical industry.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, utilizes radium-224 to target micro-metastases post-surgery, and is currently under investigation in clinical trials across the US, UK, and Europe.
YTD Price Performance: -85.45%
Average Trading Volume: 87,196
Current Market Cap: NOK186.4M
For a thorough assessment of BRRGF stock, go to TipRanks’ Stock Analysis page.